BeiGene, Ltd. (ONC) — Quality & forensics
As of 2026-10-30 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 31
- Quality 64
- Growth 86
- Balance sheet 80
- Cash quality 82
- Capital allocation 13
- Momentum 86
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the ONC chart & overview · the earnings record
FAQ · from the current data · as of 2026-10-30
Quick answers
What is BeiGene, Ltd.'s Closelooknet quality reading?
The composite reads 65/100 across 7 modules, as of 2026-10-30: valuation 31, quality 64, growth 86, balance sheet 80, cash quality 82, capital allocation 13, momentum 86. Closelooknet scores are research diary readings, not ratings or investment advice.
What is BeiGene, Ltd.'s Altman Z-Score?
6.71, which sits in the safe zone (above 2.99) as of 2026-10-30. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is BeiGene, Ltd.'s Piotroski F-Score?
7 of 9, as of 2026-10-30. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does BeiGene, Ltd.'s Beneish M-Score indicate?
-2.64 — below the −1.78 manipulation-risk threshold, as of 2026-10-30. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- HALO Halozyme Therapeutics Incindustry
- UCB.BR UCB SAindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- KRYS Krystal Biotech Incindustry
- KOD Kodiak Sciences Incindustry
- REPL Replimune Group Incindustry
- MRNA Moderna Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- ABSI Absci Corpindustry
- EXEL Exelixis Incindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- XNCR Xencor Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- ADMA ADMA Biologics Incindustry
- VRDN Viridian Therapeutics Incindustry
- IRON Disc Medicine Inc.industry
- BHVN Biohaven Ltd.industry